View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 14, 2021

Immune-Onc doses first patient in Phase I solid tumour treatment trial

The dose-escalation trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of IO-108.

Immune-Onc Therapeutics has dosed the first subject in the Phase I clinical trial of IO-108 to treat solid tumours.

A new antagonist antibody, IO-108 acts on the myeloid checkpoint Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2 / ILT4).

The multicentre, dose-escalation Phase I trial will analyse the tolerability, safety, pharmacokinetics, and pharmacodynamics of IO-108 as a single agent and along with pembrolizumab.

Pembrolizumab is an anti-programmed cell death protein 1 (PD-1) antibody.

The trial will also analyse biomarkers to facilitate a mechanistic interpretation of clinical data and inform upcoming trials.

It might also aid in detecting initial efficacy signals, the company noted.

Immune-Onc plans to evaluate the efficacy, safety and tolerability of IO-108 alone and with pembrolizumab in indication-specific expansion groups on determining the recommended dose for the Phase II trial.

The company anticipates reporting top-line trial results next year.

Immune-Onc chief medical officer Paul Woodard said: “The first patient dosed in our Phase I clinical trial for IO-108 represents a critical milestone in advancing the development and understanding of Immune-Onc’s novel myeloid checkpoint inhibitors targeting the LILRB family of immune inhibitory receptors.

“We believe our scientific platform holds vast promise and today’s news reflects our commitment to rapidly advancing programs in our portfolio that have the potential to improve outcomes for cancer patients.”

On treating several primary human immune cell systems having myeloid cells with IO-108 in preclinical studies, improved proinflammatory responses to various stimuli pertinent to anti-tumour immunity were observed.

Immune-Onc noted that IO-108 monotherapy could reverse the anti-inflammatory myeloid cell phenotype caused by ‘tumour conditioning’.

IO-108 also boosts monocyte differentiation into pro-inflammatory dendritic cells.

The clinical-stage cancer immunotherapy firm focuses on discovering and developing new myeloid checkpoint inhibitors for the treatment of cancer.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy